NEW · Biotechnology

ABBV

AbbVie Inc · $457.54B
266.81
+3.05%

Price

252 sessions shown
1M3M6M1Y2Y5Y

Technicals

from daily closes
RSI · 14 day
60.1
Avg true range · 14d
2.35%
Volatility · 20d annualised
26.1%
Trend · 20d vs 50d
Up
vs 20-day average
5.54%
vs 50-day average
8.25%
vs 200-day average
18.01%
200-day average
226.08

Internals

where it sits, and how hard it is being traded
52-week low
190.75
52-week high
267.47
Volume vs its 20-day avg
0.60×
Beta vs the market
0.22
Sitting 99% of the way up its 52-week range (190.75267.47)

Swings

prices it actually turned at — highest or lowest of the surrounding 11 sessions
Turned down · Jul 2
261.64
Turned down · Jul 17
260.96
Turned down · Jul 29
267.47
Turned up · Jun 18
215.37
Turned up · Jul 15
243.07
Turned up · Aug 6
241.20

Fundamentals

P/E
70.24
Fwd P/E
P/S
6.88
P/B
94.44
EV/EBITDA
28.76
ROE
95.6%
ROA
4.7%
Gross margin
72.8%
Net margin
Debt / equity
20.19
Rev growth
10.4%
EPS growth
-29.0%

Earnings

Next report
Oct 29, 2026
EPS expected
3.92
Beat in last 4
3 of 4
2026-06-30reported 3.65 vs 3.68 expected-0.7%
2026-03-31reported 2.65 vs 2.65 expected+0.2%
2025-12-31reported 2.71 vs 2.71 expected+0.2%
2025-09-30reported 1.86 vs 1.81 expected+2.7%

Analyst coverage

38 analysts · as of 2026-08-01
Strong buy
9
Buy
22
Hold
7
Sell
0
Strong sell
0

News

stories naming this company, last 21 days
Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $300 · Benzinga · Aug 17
Wolfe Research Upgrades AbbVie (ABBV) · Fintel · Aug 14
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? · Yahoo · Aug 13
Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth? · Yahoo · Aug 13
The Sharpest Exchanges From ABBV's Earnings Call · Yahoo · Aug 13
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation · Yahoo · Aug 13

Every figure here is measured from live market data as of Aug 19, 07:41 PM. Nothing is estimated or filled in — where a figure shows the source had no value for it, and a section you don’t see had no data at all. This describes what the market has already done. It is not a forecast, and not financial advice.

← Scan for anotherSee the decision card →